Arthritis Research UK Primary Care Centre, Research Institute for Primary Care & Health Sciences, Keele University, Staffordshire, UK.
Eur J Pain. 2019 May;23(5):908-922. doi: 10.1002/ejp.1357. Epub 2019 Jan 31.
Long-term opioid prescribing for musculoskeletal pain is controversial due to uncertainty regarding effectiveness and safety. This study examined the risks of a range of adverse events in a large cohort of patients prescribed long-term opioids using the UK Clinical Practice Research Datalink.
Patients with musculoskeletal conditions starting a new long-term opioid episode (defined as ≥3 opioid prescriptions within 90 days) between 2002 and 2012 were included. Primary outcomes: major trauma and intentional overdose (any).
addiction (any), falls, accidental poisoning, attempted suicide/self-harm, gastrointestinal pathology and bleeding, and iron deficiency anaemia. "Control" outcomes (unrelated to opioid use): incident eczema and psoriasis.
A total of 98,140 new long-term opioids users (median age 61, 41% male) were followed for (median) 3.4 years. Major trauma risk increased from 285 per 10,000 person-years without long-term opioids to 369/10,000 for a long-term opioid episode (<20 mg MED), 382/10,000 (20-50 mg MED), and 424/10,000 (≥50 mg MED). Adjusted hazard ratios were 1.09 (95% CI; 1.04, 1.14 for <20 mg MED vs. not being in an episode of long-term prescribing), 1.24 (95% CI; 1.16, 1.32: 20-50 mg MED) and 1.34 (95% CI; 1.20, 1.50: ≥50 mg MED). Significant dose-dependent increases in the risk of overdose (any type), addiction, falls, accidental poisoning, gastrointestinal pathology, and iron deficiency anaemia were also found.
Patients prescribed long-term opioids are vulnerable to dose-dependent serious adverse events. Opioid prescribing should be reviewed before long-term use becomes established, and periodically thereafter to ensure that patients are not being exposed to increased risk of harm, which is not balanced by therapeutic benefit.
Long-term opioid use is associated with serious adverse events such as major trauma, addiction and overdose. The risk increases with higher opioid doses. Opioid prescribing should be reviewed before long-term use becomes established, and periodically thereafter to assess ongoing effectiveness.
由于对有效性和安全性的不确定性,长期开具阿片类药物治疗肌肉骨骼疼痛存在争议。本研究使用英国临床实践研究数据库(UK Clinical Practice Research Datalink),在大量接受长期阿片类药物治疗的患者中,检查了一系列不良事件的风险。
纳入 2002 年至 2012 年期间新开始长期阿片类药物治疗(定义为 90 天内开具≥3 张阿片类药物处方)的肌肉骨骼疾病患者。主要结局:主要创伤和故意过量(任何类型)。
成瘾(任何类型)、跌倒、意外中毒、自杀/自残、胃肠道病理和出血以及缺铁性贫血。“对照”结局(与阿片类药物使用无关):新发生湿疹和银屑病。
共纳入 98140 例新开始长期阿片类药物治疗的患者(中位年龄 61 岁,41%为男性),中位随访 3.4 年。主要创伤风险从无长期阿片类药物治疗的每 10000 人年 285 例增加到每 10000 人年 369 例(短期治疗组:<20mg MED)、382 例(20-50mg MED)和 424 例(≥50mg MED)。调整后的风险比为 1.09(95%CI;1.04,1.14 与短期治疗组相比,即无长期治疗期),1.24(95%CI;1.16,1.32:20-50mg MED)和 1.34(95%CI;1.20,1.50:≥50mg MED)。还发现,剂量依赖性地增加了过量(任何类型)、成瘾、跌倒、意外中毒、胃肠道病理和缺铁性贫血的风险。
长期接受阿片类药物治疗的患者易发生与剂量相关的严重不良事件。在长期使用成为既定事实之前,应审查阿片类药物的处方,此后定期进行审查,以确保患者不会面临增加的伤害风险,而这种风险不会因治疗益处而得到平衡。
长期使用阿片类药物与严重不良事件有关,如主要创伤、成瘾和过量。风险随着阿片类药物剂量的增加而增加。在长期使用成为既定事实之前,应审查阿片类药物的处方,并在此后定期评估,以评估其持续有效性。